News & Media

Filter by month

04/30/20

Starton Therapeutics Files PCT and US Patent Application for Continuous Delivery of Lenalidomide and Class of Immunomodulatory Agents

NEW YORK, N.Y., April 30, 2020 – Starton Therapeutics Inc. (“Starton” or the “Company”), a biotechnology company focused on transforming standard of care therapeutics, today announced that it has filed PCT (“Patent Cooperation Treaty”)…

Read more

12/27/19

Starton Successfully Completes Proof of Concept Study for Transdermal Lenalidomide

NEW YORK, Dec. 27, 2019 (GLOBE NEWSWIRE) — Starton Therapeutics Inc. (“Starton” or the “Company”), a biotechnology company focused on transforming standard of care therapeutics, today announced the completion of a proof of concept…

Read more

12/26/19

Starton Therapeutics: Announcing Name Change for ChemioCare Inc

DECEMBER 26 2019, NEW YORK – ChemioCare USA Inc. (“ChemioCare” or the “Company”), a biotechnology company focused on transforming standard of care therapeutics, today announced it has changed the name of the Company to Starton Therapeutics, Inc….

Read more

12/18/19

ChemioCare Completes Successful Human Bioavailability Study for Novel 7-Day Olanzapine Transdermal Delivery System

PARP inhibitor induced nausea and vomiting program is now clinically ready to advance to Phase 3. DECEMBER 18 2019, NEW YORK – ChemioCare USA Inc. (“ChemioCare” or the “Company”), a biotechnology company focused on transforming…

Read more

08/29/19

ChemioCare Strengthens its Proposed Slate of Directors with the Nomination of Multiple Myeloma Expert Dr. Mohamad Hussein

ChemioCare USA Inc. (“ChemioCare” or the “Company”), a platform company focused on proprietary transdermal delivery, announced today the addition of Dr. Mohamad Hussein to the Company’s proposed slate of directors for election at the…

Read more

04/29/19

ChemioCare Announces Appointment of Roy F. Waldron to Its Board of Directors

ChemioCare USA Inc. (“ChemioCare” or the “Company”), a platform company focused on proprietary transdermal delivery, announced today the appointment of Roy F. Waldron to its Board of Directors, effective immediately. Mr. Waldron brings over…

Read more

04/23/19

ChemioCare Announces Initiation of PETT Based (Permeation Enhanced Transdermal Technology) Lenalidomide Program

ChemioCare USA Inc. (“ChemioCare” or the “Company”), a platform company focused on proprietary transdermal delivery, announced today the Company is initiating development of a transdermal formulation of lenalidomide, which is currently marketed in an…

Read more

02/06/19

ChemioCare Reports Positive Animal Study Results for CMIO-Ondan Patch

ChemioCare USA Inc. (“ChemioCare” or the “Company”), a platform company based on proprietary transdermal delivery, today announced the minipig safety and pharmacokinetic study results of CMIO-Ondan, a 5-day transdermal formulation of ondansetron for the…

Read more

01/07/19

ChemioCare Strengthens Executive Management Team

ChemioCare USA Inc. (“ChemioCare” or the “Company”), a Platform Company based on proprietary transdermal delivery today announced the appointment of Jamie Oliver, Pharm.D PhD. to the Company as Chief Medical Officer and Chris Chipman,…

Read more

01/04/19

ChemioCare Initiates Development Program in Pediatric CINV

ChemioCare USA Inc. (“ChemioCare” or the “Company”), a platform company focused on proprietary transdermal delivery today announced that its Adult Ondansetron 5-day adhesive transdermal patch will initiate development and be adapted for use in…

Read more

10/18/18

ChemioCare Expands Proprietary Transdermal Platform

ChemioCare USA Inc. (“ChemioCare” or the “Company”), a biotech company focused on transforming patient outcomes in cancer supportive care, today announces a successful Drug Enforcement Administration (DEA) registration: ChemioCare’s exclusive formulation development partner, Transdermal…

Read more

07/30/18

ChemioCare Announces Addition of Three Experienced Team Members

ChemioCare USA Inc. (“ChemioCare” or the “Company”), a biotech company focused on transforming chemotherapy induced nausea and vomiting (CINV) outcomes through transdermal patch technology, today announced a strengthening of its Board and Management team….

Read more

05/01/18

ChemioCare Announces Addition of Chief Medical Advisor and Director

ChemioCare USA Inc. (“ChemioCare” or the “Company”), a biotech company focused on transforming chemotherapy induced nausea and vomiting (CINV) outcomes through transdermal patch technology, today announced the addition of two experienced professionals to its…

Read more

03/06/18

ChemioCare Formed to Transform Chemo-Induced Emesis Outcomes Through Patch Technology

NEW YORK – ChemioCare USA Inc. (“ChemioCare”) today announced it will be leveraging novel transdermal patch technology for the treatment of chemotherapy-induced nausea and vomiting. CINV is a therapeutic area with significant unmet medical needs,…

Read more